Protagonist Therapeutics (PTGX) EBIT Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) reported EBIT Margin of 6.47% for Q1 2026, up 6171.0% on a YoY basis from 0.1% in Q1 2025, and up 99.04% sequentially from 677.09% in Q4 2025.
Protagonist Therapeutics (PTGX) EBIT Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 10 years of EBIT Margin data on file, last reported at 6.47% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 6171.0% year-over-year to 6.47%; the trailing twelve-month figure through Mar 2026 stood at 192.36% (down 20582.0% YoY), and the FY2025 full-year result was 343.63%, down 40184.0% from the prior year.
- EBIT Margin advanced to 6.47% in Q1 2026, from 677.09% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 80.92% in Q1 2024 to a low of 4824.56% in Q2 2022.
- A 5-year average of 751.28% and a median of 379.58% in 2022 frame the typical range for EBIT Margin.
- Peak annual rise in EBIT Margin reached 30605 bps in 2022, while the deepest fall reached 346112 bps in 2022.
- Tracing PTGX's EBIT Margin over 5 years: stood at 4824.56% in 2022, then surged by 101 bps to 46.1% in 2023, then surged by 67 bps to 76.84% in 2024, then slumped by 981 bps to 677.09% in 2025, then jumped by 99 bps to 6.47% in 2026.
- Business Quant data shows PTGX's EBIT Margin at 6.47% in Q1 2026, 677.09% in Q4 2025, and 985.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -6.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.47% |
| Dec 31, 2025 | -677.09% |
| Sep 30, 2025 | -985.17% |
| Jun 30, 2025 | -758.04% |
| Mar 31, 2025 | -68.18% |
| Dec 31, 2024 | 76.84% |
| Sep 30, 2024 | -886.70% |
| Jun 30, 2024 | -930.96% |
| Mar 31, 2024 | 80.92% |
| Dec 31, 2023 | 46.10% |
| Jun 30, 2022 | -4,824.56% |
| Mar 31, 2022 | -82.07% |
| Dec 31, 2021 | -429.57% |
| Sep 30, 2021 | -329.83% |
| Jun 30, 2021 | -1,363.44% |
| Mar 31, 2021 | -388.12% |
| Dec 31, 2020 | -333.27% |
| Sep 30, 2020 | -59.26% |
| Jun 30, 2020 | -293.02% |
| Mar 31, 2020 | -540.09% |